DE69617916D1 - Beta-a4 peptid spezifischer monoklonaler antikörper - Google Patents

Beta-a4 peptid spezifischer monoklonaler antikörper

Info

Publication number
DE69617916D1
DE69617916D1 DE69617916T DE69617916T DE69617916D1 DE 69617916 D1 DE69617916 D1 DE 69617916D1 DE 69617916 T DE69617916 T DE 69617916T DE 69617916 T DE69617916 T DE 69617916T DE 69617916 D1 DE69617916 D1 DE 69617916D1
Authority
DE
Germany
Prior art keywords
instant invention
monoclonal antibody
beta
specific monoclonal
peptide specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69617916T
Other languages
English (en)
Other versions
DE69617916T2 (de
Inventor
Gerhard Konig
Paul Graham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Bayer Corp
Original Assignee
Bayer AG
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23534218&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69617916(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer AG, Bayer Corp filed Critical Bayer AG
Publication of DE69617916D1 publication Critical patent/DE69617916D1/de
Application granted granted Critical
Publication of DE69617916T2 publication Critical patent/DE69617916T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE69617916T 1995-02-14 1996-02-14 Beta-a4 peptid spezifischer monoklonaler antikörper Expired - Fee Related DE69617916T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/388,463 US5786180A (en) 1995-02-14 1995-02-14 Monoclonal antibody 369.2B specific for β A4 peptide
PCT/US1996/002491 WO1996025435A1 (en) 1995-02-14 1996-02-14 MONOCLONAL ANTIBODY SPECIFIC FOR βA4 PEPTIDE

Publications (2)

Publication Number Publication Date
DE69617916D1 true DE69617916D1 (de) 2002-01-24
DE69617916T2 DE69617916T2 (de) 2002-05-16

Family

ID=23534218

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69637150T Expired - Lifetime DE69637150T3 (de) 1995-02-14 1996-02-14 Für das Beta-A4 (1-42) Peptid spezifischer monoklonaler Antikörper
DE69617916T Expired - Fee Related DE69617916T2 (de) 1995-02-14 1996-02-14 Beta-a4 peptid spezifischer monoklonaler antikörper

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69637150T Expired - Lifetime DE69637150T3 (de) 1995-02-14 1996-02-14 Für das Beta-A4 (1-42) Peptid spezifischer monoklonaler Antikörper

Country Status (11)

Country Link
US (3) US5786180A (de)
EP (3) EP1842859B1 (de)
JP (1) JP3115606B2 (de)
AT (2) ATE210681T1 (de)
CA (1) CA2212887C (de)
DE (2) DE69637150T3 (de)
DK (2) DK1160256T4 (de)
ES (3) ES2400674T3 (de)
HK (1) HK1114105A1 (de)
PT (2) PT1160256E (de)
WO (1) WO1996025435A1 (de)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6114133A (en) * 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US20060178302A1 (en) * 1997-02-05 2006-08-10 Northwestern University & The University Of Southern California Amyloid beta protein (globular assembly and uses thereof)
US20030068316A1 (en) * 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
US8173127B2 (en) * 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
AU743827B2 (en) 1997-04-09 2002-02-07 Intellect Neurosciences, Inc. Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
ES2136535B1 (es) * 1997-04-15 2000-08-16 Consejo Superior Investigacion Peptido sintetico para la produccion de anticuerpos contra el peptido beta amiloide 1-42.
AU740445B2 (en) * 1997-04-16 2001-11-01 Wyeth Beta-amyloid peptide-binding proteins and polynucleotides encoding the same
US7005295B1 (en) 1997-04-16 2006-02-28 Wyeth β-amyloid peptide-binding proteins and polynucleotides encoding the same
US6787319B2 (en) 1997-04-16 2004-09-07 American Home Products Corp. β-amyloid peptide-binding proteins and polynucleotides encoding the same
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
AU2003262458B2 (en) * 1998-05-21 2008-06-19 University Of Tennessee Research Foundation Methods for amyloid removal using anti-amyloid antibodies
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
CN1344275A (zh) 1998-05-21 2002-04-10 田纳西州立大学研究股份有限公司 用淀粉样蛋白抗体除去淀粉样蛋白的方法
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
JP5249482B2 (ja) * 1999-06-16 2013-07-31 ボストン・バイオメデイカル・リサーチ・インステイテユート インビボのβ−アミロイドレベルの免疫学的制御
SI1481992T1 (sl) 2000-02-24 2017-01-31 Washington University St. Louis Humanizirana protitelesa, ki vežejo amiloidni peptid beta
US7485616B2 (en) * 2000-04-05 2009-02-03 University Of Tennessee Research Foundation Methods of investigating, diagnosing, and treating amyloidosis
JP2003516929A (ja) * 2000-06-01 2003-05-20 ニユーララブ・リミテツド アミロイド形成性疾患の予防および治療
WO2002003911A2 (en) 2000-07-07 2002-01-17 Lars Lannfelt Prevention and treatment of alzheimer's disease
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US6815175B2 (en) * 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
WO2002088307A2 (en) 2001-04-30 2002-11-07 Eli Lilly And Company Humanized antibodies
US7318923B2 (en) 2001-04-30 2008-01-15 Eli Lilly And Company Humanized anti-βantibodies
EP1944040B1 (de) 2001-08-17 2012-08-01 Washington University Assay-Verfahren für Alzheimer
EP1481245A4 (de) * 2002-03-01 2007-06-13 Applera Corp Bestimmung der kompatibilität eines satzes chemischer modifikationen mit einer aminosäurekette
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US20040107871A1 (en) * 2002-08-09 2004-06-10 Defeo Maureen A. Aluminum trihydrate containing slurries
AU2003279216A1 (en) * 2002-10-09 2004-05-04 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US20060188512A1 (en) * 2003-02-01 2006-08-24 Ted Yednock Active immunization to generate antibodies to solble a-beta
ES2344645T3 (es) 2003-02-10 2010-09-02 Applied Molecular Evolution, Inc. Moleculas de union al abeta.
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US7807171B2 (en) 2003-07-25 2010-10-05 Ac Immune Sa Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
TWI355389B (en) * 2004-07-30 2012-01-01 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide a
AU2005297854A1 (en) * 2004-10-28 2006-05-04 Sanko Junyaku Co., Ltd. Method of examining Alzheimer's disease and diagnostic reagent
CA2587487A1 (en) * 2004-11-12 2006-05-18 Pfizer, Inc. Method of measuring amyloid-beta peptides
ES2396555T3 (es) 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
PE20061329A1 (es) 2004-12-15 2006-12-08 Neuralab Ltd Anticuerpos ab humanizados para mejorar la cognicion
WO2006081171A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
PE20061201A1 (es) * 2005-01-28 2006-11-03 Wyeth Corp Formulaciones liquidas estabilizadas de polipeptido
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
EA201100177A1 (ru) * 2005-06-17 2011-06-30 Элан Фарма Интернэшнл Лимитед СПОСОБЫ ОЧИСТКИ АНТИТЕЛ К β-АМИЛОИДУ
RU2008120027A (ru) * 2005-10-21 2009-11-27 Мерк энд Ко., Инк. (US) Анти-addl моноклональное антитело и его применение
RS53270B2 (sr) 2005-11-30 2018-05-31 Abbvie Deutschland Monoklonalna antitela protiv amiloidnog beta proteina i njihova upotreba
AU2006319358B2 (en) 2005-11-30 2012-01-19 AbbVie Deutschland GmbH & Co. KG Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
NO345996B1 (no) * 2005-12-12 2021-12-13 Ac Immune Sa A beta 1-42-spesifikke monoklonale antistoffer med terapeutiske egenskaper.
WO2007108756A1 (en) 2006-03-23 2007-09-27 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
PL2468770T3 (pl) * 2006-07-14 2018-07-31 Ac Immune S.A. Humanizowane przeciwciało przeciw amyloidowi beta
FR2903999B1 (fr) * 2006-07-19 2008-09-05 Galderma Res & Dev S N C Snc Modulateurs de sc4mol dans le traitement de l'acne ou de l'hyperseborrhee
WO2008045962A2 (en) * 2006-10-10 2008-04-17 Mayo Foundation For Medical Education And Research Methods and materials related to anti-a (beta) antibodies
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2121754B1 (de) 2007-01-18 2015-02-11 Eli Lilly and Company Pegyliertes amyloid beta fab
EP2486928A1 (de) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Verfahren zur Behandlung von Amyloidosen
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
EP2009445A1 (de) * 2007-06-29 2008-12-31 Institut Pasteur Verwendung von Einzeldomänen-Camelid-Antikörpern zur Entdeckung einer oligomeren Form eines Amyloid-Betapeptids und deren Anwendungen
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
US20100297012A1 (en) * 2007-10-05 2010-11-25 Andrea Pfeifer Humanized antibody
ES2445590T3 (es) * 2007-10-05 2014-03-04 Genentech, Inc. Uso de anticuerpo anti-amiloide beta en enfermedades oculares
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP2475428B1 (de) 2009-09-11 2015-07-01 Probiodrug AG Heterocyclische derivate als glutaminylcyclase-hemmer
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
MX336196B (es) 2010-04-15 2016-01-11 Abbvie Inc Proteinas de union a amiloide beta.
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
BR112013002297A2 (pt) 2010-07-30 2016-05-24 Ac Immune Sa anticorpos humanizados seguros e funcionais
EP3527220A1 (de) 2010-08-12 2019-08-21 AC Immune S.A. Manipulation von impfstoffen
WO2012024187A1 (en) 2010-08-14 2012-02-23 Abbott Laboratories Amyloid-beta binding proteins
EP2632434A1 (de) 2010-10-26 2013-09-04 AC Immune S.A. Konstrukt auf liposomenbasis mit einem anhand von hydrophoben einheiten modifizierten peptid
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
JP2012102131A (ja) * 2012-01-05 2012-05-31 Elan Pharma Internatl Ltd アミロイド形成性疾患の予防および治療
CN103665113A (zh) * 2012-09-14 2014-03-26 深圳市安群生物工程有限公司 人Aβ42抗原决定簇多肽、抗原、抗体、用途及试剂盒
KR102450670B1 (ko) 2012-10-15 2022-10-04 메디뮨 리미티드 아밀로이드 베타에 대한 항체
JP2016103980A (ja) * 2013-03-08 2016-06-09 パナソニックヘルスケア株式会社 ハイブリドーマ及びモノクローナル抗体
BR112016030774A2 (pt) 2014-07-10 2018-01-16 Bioarctic Neuroscience Ab anticorpo ou fragmento de ligação a antígeno do mesmo, uso de um anticorpo, métodos para redução da quantidade de protofibrilas de ?? em um indivíduo, para tratamento e/ou para profilaxia de uma doença, para medição da quantidade de protofibrilas de ?? e/ou de proteína ?? agregada em uma pessoa, e para diagnóstico de uma doença, e, composição farmacêutica
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
EP0527823A1 (de) * 1990-04-24 1993-02-24 The Regents Of The University Of California Reinigung, nachweis und verfahren zur verwendung der protease-nexin-2
US5750349A (en) * 1993-01-25 1998-05-12 Takeda Chemical Industries Ltd. Antibodies to β-amyloids or their derivatives and use thereof

Also Published As

Publication number Publication date
EP0809656A1 (de) 1997-12-03
US5693753A (en) 1997-12-02
ES2288896T5 (es) 2012-02-16
DK1160256T4 (da) 2012-01-09
ES2167548T3 (es) 2002-05-16
EP1160256B8 (de) 2009-04-01
DE69637150D1 (de) 2007-08-09
EP1842859A3 (de) 2007-11-28
EP1160256A2 (de) 2001-12-05
PT809656E (pt) 2002-06-28
EP1842859B1 (de) 2013-01-09
CA2212887C (en) 2006-10-10
US5786180A (en) 1998-07-28
CA2212887A1 (en) 1996-08-22
ATE210681T1 (de) 2001-12-15
WO1996025435A1 (en) 1996-08-22
HK1114105A1 (en) 2008-10-24
DK0809656T3 (da) 2002-03-18
DE69637150T2 (de) 2008-02-28
EP1160256B2 (de) 2011-11-09
ATE365750T1 (de) 2007-07-15
US5679531A (en) 1997-10-21
EP1160256A3 (de) 2002-11-06
EP1842859A2 (de) 2007-10-10
DE69637150T3 (de) 2012-03-15
ES2288896T3 (es) 2008-02-01
EP1160256B1 (de) 2007-06-27
JP3115606B2 (ja) 2000-12-11
DE69617916T2 (de) 2002-05-16
ES2400674T3 (es) 2013-04-11
PT1160256E (pt) 2007-10-08
EP0809656B1 (de) 2001-12-12
DK1160256T3 (da) 2007-10-22
JPH10509736A (ja) 1998-09-22
MX9706189A (es) 1997-11-29

Similar Documents

Publication Publication Date Title
DE69617916T2 (de) Beta-a4 peptid spezifischer monoklonaler antikörper
DE69228701D1 (de) Fragmente von Prion Proteinen.
AT500379B8 (de) Tau-proteine
DE69535375D1 (de) Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper
DE69129302D1 (de) Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen
DE69328864T2 (de) Reinigung von proteinen
DK0500659T3 (da) Monoklonale antistoffer.
DE60129239D1 (de) Kit und verfahren zur bestimmung von protein esm-1
DK0594576T3 (da) Immunoafprøvninger for og monoklonale antistoffer over for prothrombin-aktivering-peptider og deres nedbrydningsprodukter
DE69615843T2 (de) Il-8 antagonisten zur behandlung von asthma
DE69607034T2 (de) Pcna bindende substanz
EP0725081A4 (de) MONOKLONALER ANTIKÖRPER GEGEN MxA DES MENSCHLICHEN Mx PROTEINS
PT723552E (pt) Oligopeptidos derivados de fragmentos de proteina reactiva c
DE59709495D1 (de) Antikörper und immunoassay zum Nachweis von MIA
HUP0003029A2 (hu) Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk
ATE171545T1 (de) Verfahren zur bestimmung des lysingehaltes von samen
GB2333295A (en) Modified protein G and fragments thereof

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee